NASDAQ$NUTX
Nutex Health Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close
Briefing
Nutex Health Inc reported strong revenue growth in Q2 2025 driven by higher patient volumes and improved reimbursement rates.
For the three months ended June 30, 2025, Nutex Health Inc achieved total revenue of $244.0 million, a significant increase from the prior year, primarily from its hospital division. The company recorded operating income of $33.7 million but reported a net loss attributable to shareholders of $17.7 million due to substantial stock-based compensation expenses. Cash and cash equivalents rose to $96.7 million, reflecting improved operating cash flows.
- Total revenue reached $243.985 million, up 220% year-over-year, fueled by 10.6% growth in patient visits and higher IDR arbitration recoveries.
- Hospital division revenue was $236.302 million while population health management contributed $7.683 million.
- Operating income was $33.679 million; however, net loss attributable to Nutex Health Inc. was $17.697 million after $78.747 million in stock-based compensation.
- Cash position strengthened to $96.733 million with operating cash flow of $78.222 million for the first half of 2025.
Headline financials
Revenue & EPS history
Nutex Health Inc · Revenue · Quarterly
$244M
Revenue by segment
Nutex Health Inc · $244M total across 2 segments · Q2 2025
- Hospital Division$236M—96.9%
- Population Health Management$7.68M—3.1%
Forward guidance
No explicit forward-looking guidance provided in the filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
+1.9%
Avg return
Earnings day
+17.2%
Avg return
5 days after
+21.1%
Avg return
30 days after
62%
8 / 13 earnings
Positive
+22.4%
Q1 2022
Best reaction
-14.3%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +6.4% | +8.0% | +14.4% | |
| Q4 2025 | -14.3% | -14.1% | -4.2% | |
| Q3 2025 | +0.0% | +32.9% | +64.1% | |
| Q1 2025 | +1.0% | +40.2% | +0.2% | |
| Q3 2024 | +6.3% | +38.2% | +39.3% | |
| Q2 2024 | +0.9% | +62.7% | +173.1% | |
| Q1 2024 | +6.2% | +14.8% | +0.7% | |
| Q3 2023 | +0.0% | -6.0% | -22.8% | |
| Q2 2023 | +3.6% | +0.9% | -20.1% | |
| Q1 2023 | +8.9% | +10.3% | -17.8% | |
| Q3 2022 | -9.2% | +1.7% | +59.7% | |
| Q2 2022 | -8.2% | -27.9% | -53.8% | |
| Q1 2022 | +22.4% | +61.8% | +41.2% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro